Dysmenorrhea Treatment Market

Executive Summary

Dysmenorrhea Treatment Market was valued at US $4,699.24 million in 2021 and is projected to grow at 8.49% CAGR over the forecast period to reach US $7,662.90 million by 2027. Dysmenorrhea Treatment Market represented US $706.79 million opportunity over 2019-2021 and estimated to create US $2,963.66 million opportunity in 2027 over 2021.

Dysmenorrhea Treatment from Consainsights analyses the Dysmenorrhea Treatment Market in the Life Sciences industry over the forecast period to 2027.

Dysmenorrhea Treatment research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Dysmenorrhea Treatment segmentation includes Treatment Type, Type and Geography.

Based on the Treatment Type, the Dysmenorrhea Treatment analysis covers Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Hormonal Therapy.

In Treatment Type segment, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) segment has highest cagr growth of 7.51%.

Based on the Type, the Dysmenorrhea Treatment analysis covers Primary Dysmenorrhea, Secondary Dysmenorrhea.

In Type segment, Primary Dysmenorrhea segment has highest cagr growth of 7.51%.

Based on the region, the Dysmenorrhea Treatment analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Novartis AG, Bayer AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sanofi, Pfizer Inc, GlaxoSmithKline Plc, Focus Consumer Healthcare, Johnson & Johnson, Alvogen and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Treatment Type

Introduction

In 2021, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) segment has the highest revenue of US $2,887.16 million and is expected to grow at CAGR of 7.51% by 2027 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) segment has highest cagr growth of 7.51%.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) segment was valued at US $2,452.92 million in 2019 and is projected to grow at 7.51% CAGR over the forecast period to reach US $4,708.00 million by 2027. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) segment represented US $434.25 million opportunity over 2019-2021 and estimated to create US $1,820.84 million opportunity in 2027 over 2021.

Hormonal Therapy

Hormonal Therapy segment was valued at US $1,539.53 million in 2019 and is projected to grow at 7.51% CAGR over the forecast period to reach US $2,954.89 million by 2027. Hormonal Therapy segment represented US $272.55 million opportunity over 2019-2021 and estimated to create US $1,142.82 million opportunity in 2027 over 2021.

Type

Introduction

In 2021, Primary Dysmenorrhea segment has the highest revenue of US $3,870.09 million and is expected to grow at CAGR of 7.51% by 2027 Primary Dysmenorrhea segment has highest cagr growth of 7.51%.

Primary Dysmenorrhea

Primary Dysmenorrhea segment was valued at US $3,288.00 million in 2019 and is projected to grow at 7.51% CAGR over the forecast period to reach US $6,310.83 million by 2027. Primary Dysmenorrhea segment represented US $582.08 million opportunity over 2019-2021 and estimated to create US $2,440.74 million opportunity in 2027 over 2021.

Secondary Dysmenorrhea

Secondary Dysmenorrhea segment was valued at US $704.44 million in 2019 and is projected to grow at 7.51% CAGR over the forecast period to reach US $1,352.07 million by 2027. Secondary Dysmenorrhea segment represented US $124.71 million opportunity over 2019-2021 and estimated to create US $522.92 million opportunity in 2027 over 2021.